Regencell Bioscience Holdings Limited (RGC)
USD 36.67
(29.85%)
USD 36.67
(29.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.99 Million USD | -36.38% |
| 2023 | 6.27 Million USD | -17.64% |
| 2022 | 7.61 Million USD | 451.47% |
| 2021 | 1.38 Million USD | 70.04% |
| 2020 | 812.37 Thousand USD | 107.77% |
| 2019 | 390.99 Thousand USD | -99.97% |
| 2018 | 1.31 Billion USD | -19.43% |
| 2017 | 1.62 Billion USD | 2.87% |
| 2016 | 1.58 Billion USD | 32.41% |
| 2015 | 1.19 Billion USD | 0.0% |
| 2013 | 1.15 Billion USD | 9.93% |
| 2012 | 1.05 Billion USD | -14.51% |
| 2011 | 1.23 Billion USD | -13.38% |
| 2010 | 1.42 Billion USD | -42.77% |
| 2009 | 2.48 Billion USD | 0.0% |
| 2007 | 2.33 Billion USD | 2.18% |
| 2006 | 2.28 Billion USD | 6.66% |
| 2005 | 2.14 Billion USD | 1.71% |
| 2004 | 2.11 Billion USD | 0.0% |
| 2002 | 1.85 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 2.42 Million USD | 0.0% |
| 2024 Q2 | 1155.93 USD | 0.0% |
| 2024 Q1 | 1155.93 USD | -99.94% |
| 2023 FY | 6.27 Million USD | -17.64% |
| 2023 Q1 | 1657.62 USD | -99.95% |
| 2023 Q2 | 3.42 Million USD | 206794.16% |
| 2023 Q4 | 2.07 Million USD | 150930.0% |
| 2023 Q3 | 1373.55 USD | -99.96% |
| 2022 Q3 | 1967.87 USD | -99.95% |
| 2022 Q4 | 3.35 Million USD | 170361.91% |
| 2022 FY | 7.61 Million USD | 451.47% |
| 2022 Q1 | 1829.41 USD | 261.22% |
| 2022 Q2 | 3.65 Million USD | 199904.81% |
| 2021 FY | 1.38 Million USD | 70.04% |
| 2021 Q3 | 506.45 USD | 203.4% |
| 2021 Q4 | 506.45 USD | -0.0% |
| 2021 Q2 | 166.92 USD | 0.0% |
| 2021 Q1 | 166.92 USD | -35.09% |
| 2020 Q2 | 149.01 USD | 0.0% |
| 2020 FY | 812.37 Thousand USD | 107.77% |
| 2020 Q4 | 257.18 USD | -0.0% |
| 2020 Q3 | 257.18 USD | 72.59% |
| 2020 Q1 | 149.01 USD | 0.0% |
| 2019 FY | 390.99 Thousand USD | -99.97% |
| 2018 FY | 1.31 Billion USD | -19.43% |
| 2018 Q2 | 439 Million USD | 5.35% |
| 2018 Q1 | 416.7 Million USD | 0.43% |
| 2017 Q4 | 414.9 Million USD | 2.42% |
| 2017 Q3 | 405.1 Million USD | -3.25% |
| 2017 Q2 | 418.7 Million USD | 1.48% |
| 2017 Q1 | 412.6 Million USD | 3.43% |
| 2017 FY | 1.62 Billion USD | 2.87% |
| 2016 Q4 | 398.9 Million USD | 0.76% |
| 2016 FY | 1.58 Billion USD | 32.41% |
| 2016 Q3 | 395.9 Million USD | -4.9% |
| 2016 Q2 | 416.3 Million USD | 6.42% |
| 2016 Q1 | 391.2 Million USD | -0.86% |
| 2015 FY | 1.19 Billion USD | 0.0% |
| 2015 Q4 | 394.6 Million USD | 4.2% |
| 2015 Q2 | 325.9 Million USD | 16.1% |
| 2015 Q3 | 378.7 Million USD | 16.2% |
| 2015 Q1 | 280.7 Million USD | -5.58% |
| 2014 Q4 | 297.3 Million USD | 2.52% |
| 2014 Q2 | 303.2 Million USD | 2.33% |
| 2014 Q1 | 296.3 Million USD | 1.13% |
| 2014 Q3 | 290 Million USD | -4.35% |
| 2013 Q4 | 293 Million USD | 10.03% |
| 2013 FY | 1.15 Billion USD | 9.93% |
| 2013 Q2 | 276.9 Million USD | 4.53% |
| 2013 Q1 | 264.9 Million USD | 1.26% |
| 2013 Q3 | 266.3 Million USD | -3.83% |
| 2012 Q4 | 261.6 Million USD | 4.35% |
| 2012 FY | 1.05 Billion USD | -14.51% |
| 2012 Q1 | 270.9 Million USD | -23.17% |
| 2012 Q2 | 259.1 Million USD | -4.36% |
| 2012 Q3 | 250.7 Million USD | -3.24% |
| 2011 Q3 | 337.8 Million USD | 11.67% |
| 2011 FY | 1.23 Billion USD | -13.38% |
| 2011 Q1 | 361.8 Million USD | -41.7% |
| 2011 Q2 | 302.5 Million USD | -16.39% |
| 2011 Q4 | 352.6 Million USD | 4.38% |
| 2010 Q1 | 635 Million USD | -8.37% |
| 2010 FY | 1.42 Billion USD | -42.77% |
| 2010 Q4 | 620.6 Million USD | -7.65% |
| 2010 Q3 | 672 Million USD | 83.66% |
| 2010 Q2 | 365.9 Million USD | -42.38% |
| 2009 Q2 | 640 Million USD | -6.16% |
| 2009 Q3 | 603 Million USD | -5.78% |
| 2009 Q1 | 682 Million USD | 11.62% |
| 2009 FY | 2.48 Billion USD | 0.0% |
| 2009 Q4 | 693 Million USD | 14.93% |
| 2008 Q1 | 635 Million USD | 5.83% |
| 2008 Q4 | 611 Million USD | 10.29% |
| 2008 Q3 | 554 Million USD | 1.84% |
| 2008 Q2 | 544 Million USD | -14.33% |
| 2007 FY | 2.33 Billion USD | 2.18% |
| 2007 Q1 | 592 Million USD | -0.67% |
| 2007 Q2 | 567 Million USD | -4.22% |
| 2007 Q3 | 560 Million USD | -1.23% |
| 2007 Q4 | 600 Million USD | 7.14% |
| 2006 Q2 | 578 Million USD | 1.23% |
| 2006 Q3 | 534 Million USD | -7.61% |
| 2006 FY | 2.28 Billion USD | 6.66% |
| 2006 Q4 | 596 Million USD | 11.61% |
| 2006 Q1 | 571 Million USD | 296.8% |
| 2005 Q4 | 143.9 Million USD | 0.84% |
| 2005 FY | 2.14 Billion USD | 1.71% |
| 2005 Q1 | 131 Million USD | 61.73% |
| 2005 Q2 | 1.6 Billion USD | 1128.24% |
| 2005 Q3 | 142.7 Million USD | -91.13% |
| 2004 Q3 | 478 Million USD | -69.67% |
| 2004 Q1 | 534 Million USD | 439.39% |
| 2004 Q2 | 1.57 Billion USD | 195.13% |
| 2004 Q4 | 81 Million USD | -83.05% |
| 2004 FY | 2.11 Billion USD | 0.0% |
| 2003 Q4 | 99 Million USD | -78.24% |
| 2003 Q2 | 1.36 Billion USD | 175.71% |
| 2003 Q3 | 455 Million USD | -66.59% |
| 2003 Q1 | 494 Million USD | -3.52% |
| 2002 FY | 1.85 Billion USD | 0.0% |
| 2002 Q4 | 512 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | 51.639% |
| Alpha Teknova, Inc. | 45.85 Million USD | 91.297% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 97.964% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 91.102% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 97.493% |
| Cosmos Health Inc. | 26.18 Million USD | 84.755% |
| Journey Medical Corporation | 54.59 Million USD | 92.689% |
| Embecta Corp. | 528.4 Million USD | 99.245% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 98.532% |
| Dynavax Technologies Corporation | 219.14 Million USD | 98.179% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 99.324% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 98.777% |
| PainReform Ltd. | 9.58 Million USD | 58.356% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 69.59% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 69.59% |
| SCYNEXIS, Inc. | 51.84 Million USD | 92.302% |
| Safety Shot Inc | 12.1 Million USD | 67.042% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -30.039% |
| Procaps Group, S.A. | 199.47 Million USD | 97.999% |
| Theratechnologies Inc. | 72.75 Million USD | 94.514% |
| Harrow Health, Inc. | 89.97 Million USD | 95.564% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | 57.748% |
| Biofrontera Inc. | 39.95 Million USD | 90.012% |
| DURECT Corporation | 43.71 Million USD | 90.87% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 99.246% |
| Cronos Group Inc. | 96.7 Million USD | 95.873% |
| OptiNose, Inc. | 85.1 Million USD | 95.31% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 98.281% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 89.806% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 141.744% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 98.729% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | 58.985% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 90.727% |
| Radius Health, Inc. | 265.92 Million USD | 98.499% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 71.166% |
| ProPhase Labs, Inc. | 37.85 Million USD | 89.456% |
| Phibro Animal Health Corporation | 260.29 Million USD | 98.467% |
| Procaps Group S.A. | 187.24 Million USD | 97.868% |
| Alvotech | 285.43 Million USD | 98.602% |
| TherapeuticsMD, Inc. | 9.82 Million USD | 59.378% |
| Viatris Inc. | 5.96 Billion USD | 99.933% |
| Rockwell Medical, Inc. | 15.37 Million USD | 74.04% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 93.33% |
| SIGA Technologies, Inc. | 22.04 Million USD | 81.894% |
| Tilray Brands, Inc. | 251.35 Million USD | 98.412% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 91.861% |
| Shineco, Inc. | 17.94 Million USD | 77.763% |
| PetIQ, Inc. | 192.72 Million USD | 97.929% |
| Incannex Healthcare Limited | 30.05 Million USD | 86.72% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.75% |
| Alimera Sciences, Inc. | 62.64 Million USD | 93.629% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -423.433% |
| Assertio Holdings, Inc. | 368.58 Million USD | 98.917% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | 32.188% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 77.589% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 81.146% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 81.033% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 97.581% |
| Hempacco Co., Inc. | 7.59 Million USD | 47.46% |
| Talphera, Inc. | 11.99 Million USD | 66.724% |
| Alvotech | 285.43 Million USD | 98.602% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 97.164% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 98.843% |
| Currenc Group, Inc. | 24 Million USD | 83.372% |
| Kamada Ltd. | 45.42 Million USD | 91.214% |
| Indivior PLC | 911 Million USD | 99.562% |
| Evoke Pharma, Inc. | 12.4 Million USD | 67.838% |
| Flora Growth Corp. | 10.57 Million USD | 62.273% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 81.033% |
| Evolus, Inc. | 189.75 Million USD | 97.897% |
| HUTCHMED (China) Limited | 436.23 Million USD | 99.085% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 97.411% |
| Akanda Corp. | 3.48 Million USD | -14.572% |